Effect of vitamin D supplementation on health status in non-vitamin D deficient people with type 2 diabetes mellitus. Issue 6 (November 2016)

• Record Type: Journal Article
• Authors: Westra, S; Krul-Poel, Y H M; van Wijland, H J; ter Wee, M M; Stam, F; Lips, P; Pouwer, F; Simsek, S
• Is Part Of: Endocrine connections. Volume 5:Issue 6(2016)
• Page Start: 61
• Page End: 69
• Publication Date: 2016-11
• Subjects: RCT -- vitamin D -- health-related quality of life -- type 2 diabetes mellitus; Endocrinology -- Periodicals; 616.4005
• DOI: 10.1530/EC-16-0070
• Languages: English
• ISSNs: 2049-3614

Abstract

Abstract : Objective: Increased levels of depressive symptoms, fatigue or pain (all dimensions of reduced health-related quality of life (HRQOL)) are common in people with type 2 diabetes mellitus (DM). Earlier studies have reported associations between low vitamin D status and fatigue and depressive symptoms. The aim of the present study was to examine the effects of vitamin D supplementation on dimensions of HRQOL in people with type 2 DM. Design: Randomised, double-blind, placebo-controlled trial. Methods: The effect of monthly cholecalciferol 50, 000 IU vs placebo on HRQOL was assessed in 275 adults with type 2 DM derived from general practices. HRQOL at baseline and after six months using the Short Form 36 Health Survey (SF-36) was collected. Linear regression analyses were used to compare the change in HRQOL over time between the vitamin D and placebo group. Results: 187/275 (68%) completed baseline and follow-up SF-36 and were included in the analysis. Median serum 25-hydroxyvitamin D almost doubled in the intervention group compared to that in the placebo group (58.5–106.0 nmol/L vs 60.0–61.5 nmol/L, respectively). A small significant difference (adjusted B: −8.90; 95% CI: −17.16 to −0.65) between both groups was seen concerning the SF-36 domain role limitations due to physical problems in disadvantage of the vitamin D group. Conclusions: Six months of vitamin D supplementation did not improve HRQOL in non-vitamin D-deficient people with type 2 DM managed on oral antidiabetic therapy.